The aims of the present study were 1) to assess the clinical relevance of serum C3M and C4M in patients with HER2-positive breast cancer scheduled to receive neoadjuvant therapy and 2) to examine the changes of these markers during systemic treatment. This evidence concerns the gene ERBB2 and breast carcinoma.